Optical coherence tomography is beneficial for measuring visual changes and the impact of comorbidities in MS, NMOSD, and ...

Research indicates that neural stem cell transplants could promote myelin repair in progressive multiple sclerosis, paving the way for innovative treatments.

A study by Cambridge researchers has shed light on how neural stem cell grafts could help restore myelin in the central nervous system. The findings suggest that neural stem cell-based therapies hold ...

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages.

In Japan alone, around 4,000 individuals have a CIDP diagnosis. Sanofi neurology development global head Erik Wallstroem stated: “The orphan drug designation of riliprubart for ...

The demyelinating diseases therapeutics market is categorized across several parameters including product type, therapeutic application, disease type, route of administration, distribution ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a long-term neurological disorder that targets your body’s nerves. Anyone can get CIDP, but it’s most common in older adults and ...

About Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare and serious autoimmune disease of the peripheral nervous system.

Demyelination is damage to the myelin sheath around nerves. Learn what causes it and how doctors treat demyelinating diseases.

(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy.

What are the different types of these nerve disorders? WebMD covers transverse myelitis, neuromyelitis optica, ADEM, and more.

Argenx’s Vyvgart Hytrulo is now approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disease that affects nerves and impairs muscle function. The drug ...